Cosmos Health Inc

Cosmos Health Inc has a market capitalization of $15.57 million and a price-to-book ratio of 0.45, indicating that the company is trading at a significant discount to its book value. The company's liquidity position is characterized by a current ratio of 1.46, suggesting it has sufficient short-term assets to cover its short-term liabilities, but its operating cash flow of -$3.41 million indicates a cash outflow from operations. The company's profitability is weak, with a net loss of $1.87 million and an operating loss of $1.84 million. Its return on equity is -5.4%, and its return on assets is -2.99%, both significantly below the industry median for pharmaceutical companies. The company's gross profit margin is 9.15%, which is also below the industry average, indicating that it is struggling to maintain profitability despite its revenue of $14.58 million. Cosmos Health Inc's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess the geographic or segment concentration of its revenue. However, the company's exposure to pharmaceuticals and medical research suggests that it may be subject to regulatory and market risks associated with the healthcare industry. The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The company's operating cash flow and free cash flow are both negative, indicating that it is not generating sufficient cash from operations to fund its activities. The company's capital expenditure of -$82,660 suggests that it is not investing in new assets, which may limit its ability to grow in the future. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges. The company's debt-to-equity ratio of 0.31 indicates a relatively low level of leverage, which is a positive sign for its financial stability. Recent events and filings do not provide specific details about the company's operations or financial performance. The company's last actual EPS was -$0.63, significantly below the mean EPS estimate of $0.08, indicating that it is underperforming relative to analyst expectations. The company's last actual revenue of $65.27 million was also below the mean revenue estimate of $103.2 million, suggesting that it is not meeting revenue targets.